{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:50:19Z","timestamp":1790682619688,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13023-016-0435-x","type":"journal-article","created":{"date-parts":[[2016,4,29]],"date-time":"2016-04-29T06:24:38Z","timestamp":1461911078000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Rethinking fatigue in Gaucher disease"],"prefix":"10.1186","volume":"11","author":[{"given":"Y.","family":"Chen Zion","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Pappadopulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Wajnrajch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Rosenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,29]]},"reference":[{"key":"435_CR1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","volume":"281","author":"PJ Meikle","year":"1999","unstructured":"Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281:249\u201354.","journal-title":"JAMA"},{"key":"435_CR2","unstructured":"Grabowski GA, Petsko GA, Kolodny EH. Gaucher disease. In: Valle D, Beaudet AL, Vogelstein B, et al,\u00a0editors. The Online Metabolic and Molecular Basis of Inherited Disease. New York, NY: McGraw-Hill; 2010. p. 1\u2013143."},{"key":"435_CR3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/asheducation.V2012.1.13.3797921","volume":"2012","author":"GA Grabowski","year":"2012","unstructured":"Grabowski GA. Gaucher disease and other storage disorders. Hematol Am Soc Hematol Educ Program. 2012;2012:13\u20138.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"435_CR4","first-page":"273","volume":"14","author":"E Sidransky","year":"2012","unstructured":"Sidransky E. Gaucher disease: insights from a rare Mendelian disorder. Discov Med. 2012;14:273\u201381.","journal-title":"Discov Med"},{"key":"435_CR5","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2009.07872.x","volume":"147","author":"PK Mistry","year":"2009","unstructured":"Mistry PK, Deegan P, Vellodi A, Cole JA, Yeh M, Weinreb NJ. Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis. Br J Haematol. 2009;147:561\u201370.","journal-title":"Br J Haematol"},{"key":"435_CR6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1006\/bcmd.2001.0480","volume":"28","author":"H Rosenbaum","year":"2002","unstructured":"Rosenbaum H, Sidransky E. Cholelithiasis in patients with Gaucher disease. Blood Cells Mol Dis. 2002;28:21\u20137.","journal-title":"Blood Cells Mol Dis"},{"key":"435_CR7","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJMoa033277","volume":"351","author":"J Aharon-Peretz","year":"2004","unstructured":"Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson\u2019s disease in Ashkenazi Jews. N Engl J Med. 2004;351:1972\u20137.","journal-title":"N Engl J Med"},{"key":"435_CR8","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","volume":"41","author":"GM Pastores","year":"2004","unstructured":"Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol. 2004;41:4\u201314.","journal-title":"Semin Hematol"},{"key":"435_CR9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.seminhematol.2004.07.010","volume":"41","author":"NJ Weinreb","year":"2004","unstructured":"Weinreb NJ, Aggio MC, Andersson HC, et al. Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin Hematol. 2004;41:15\u201322.","journal-title":"Semin Hematol"},{"key":"435_CR10","doi-asserted-by":"crossref","unstructured":"Balwani M, Burrow TA, Charrow J, et al. Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States. Mol Genet Metab. 2015. doi: 10.1016\/j.ymgme.2015.09.002 . [Epub ahead of print].","DOI":"10.1016\/j.ymgme.2015.09.002"},{"key":"435_CR11","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1023\/A:1008878425167","volume":"7","author":"RP Hayes","year":"1998","unstructured":"Hayes RP, Grinzaid KA, Duffey EB, Elsas LJ. The impact of Gaucher disease and its treatment on quality of life. Qual Life Res. 1998;7:521\u201334.","journal-title":"Qual Life Res"},{"key":"435_CR12","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.ymgme.2014.12.050","volume":"114","author":"Y Chen Zion","year":"2015","unstructured":"Chen Zion Y, Rosenbaum H. Quality of life and Gaucher disease [abstract 48]. Mol Genet Metab. 2015;114:S30.","journal-title":"Mol Genet Metab"},{"key":"435_CR13","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/01376517-199310000-00005","volume":"25","author":"CL Verderese","year":"1993","unstructured":"Verderese CL, Graham OC, Holder-McShane CA, Harnett NE, Barton NW. Gaucher\u2019s disease: a pilot study of the symptomatic responses to enzyme replacement therapy. J Neurosci Nurs. 1993;25:296\u2013301.","journal-title":"J Neurosci Nurs"},{"key":"435_CR14","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S0168-8278(94)80109-6","volume":"21","author":"C Niederau","year":"1994","unstructured":"Niederau C, Holderer A, Heintges T, Strohmeyer G. Glucocerebrosidase for treatment of Gaucher\u2019s disease: first German long-term results. J Hepatol. 1994;21:610\u20137.","journal-title":"J Hepatol"},{"key":"435_CR15","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1023\/A:1022876631088","volume":"7","author":"DM Gagnon","year":"1998","unstructured":"Gagnon DM, Pergament E, Fine BA. Demographic studies from a National Gaucher Disease Screening Program. J Genet Couns. 1998;7:385\u201399.","journal-title":"J Genet Couns"},{"key":"435_CR16","first-page":"25","volume":"3","author":"C Niederau","year":"1998","unstructured":"Niederau C, vom Dahl S, Haussinger D. First long-term results of imiglucerase therapy of type 1 Gaucher disease. Eur J Med Res. 1998;3:25\u201330.","journal-title":"Eur J Med Res"},{"key":"435_CR17","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1023\/A:1008859420641","volume":"8","author":"BJ Masek","year":"1999","unstructured":"Masek BJ, Sims KB, Bove CM, Korson MS, Short P, Norman DK. Quality of life assessment in adults with type 1 Gaucher disease. Qual Life Res. 1999;8:263\u20138.","journal-title":"Qual Life Res"},{"key":"435_CR18","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.5858\/2000-124-1239-PQCAYO","volume":"124","author":"SB Khan","year":"2000","unstructured":"Khan SB, Alkan S, Pooley R. Pathologic quiz case. A 14-year-old boy with splenomegaly. Pathologic diagnosis: Gaucher disease. Arch Pathol Lab Med. 2000;124:1239\u201340.","journal-title":"Arch Pathol Lab Med"},{"key":"435_CR19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/01.pec.0000117929.65522.d7","volume":"20","author":"ST Chou","year":"2004","unstructured":"Chou ST, Shah SS, Hodinka RL, Cohen AR. Positive heterophile antibody test and massive splenomegaly in an adolescent with previously unsuspected Gaucher disease. Pediatr Emerg Care. 2004;20:181\u20134.","journal-title":"Pediatr Emerg Care"},{"issue":"Suppl 3","key":"435_CR20","first-page":"491","volume":"31","author":"LK Tsai","year":"2008","unstructured":"Tsai LK, Chien YH, Yang CC, Hwu WL. Myopathy in Gaucher disease. J Inherit Metab Dis. 2008;31 Suppl 3:491.","journal-title":"J Inherit Metab Dis"},{"key":"435_CR21","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/GIM.0b013e3181a1b5c5","volume":"11","author":"BE Shapiro","year":"2009","unstructured":"Shapiro BE, Pastores GM, Gianutsos J, Luzy C, Kolodny EH. Miglustat in late-onset Tay-Sachs disease: a 12-month, randomized, controlled clinical study with 24\u00a0months of extended treatment. Genet Med. 2009;11:425\u201333.","journal-title":"Genet Med"},{"key":"435_CR22","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ctim.2011.12.006","volume":"20","author":"N Samuels","year":"2012","unstructured":"Samuels N, Elstein D, Lebel E, Zimran A, Oberbaum M. Acupuncture for symptoms of Gaucher disease. Complement Ther Med. 2012;20:131\u20134.","journal-title":"Complement Ther Med"},{"key":"435_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16390","volume":"16","author":"K Wyatt","year":"2012","unstructured":"Wyatt K, Henley W, Anderson L, et al. The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders. Health Technol Assess. 2012;16:1\u2013543.","journal-title":"Health Technol Assess"},{"key":"435_CR24","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/ajh.24007","volume":"90","author":"D Elstein","year":"2015","unstructured":"Elstein D, Mehta A, Hughes DA, et al. Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease. Am J Hematol. 2015;90:592\u20137.","journal-title":"Am J Hematol"},{"key":"435_CR25","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13023-015-0275-0","volume":"10","author":"J Stirnemann","year":"2015","unstructured":"Stirnemann J, Rose C, Serratrice C, et al. Impact of imiglucerase supply constraint on the therapeutic management and course of disease in French patients with Gaucher disease type 1. Orphanet J Rare Dis. 2015;10:62.","journal-title":"Orphanet J Rare Dis"},{"key":"435_CR26","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jiac.2015.08.009","volume":"22","author":"O Dulgar","year":"2016","unstructured":"Dulgar O, Eskazan AE, Ersen E, et al. Pleural tuberculosis in a patient with untreated type 1 Gaucher disease. J Infect Chemother. 2016;22:53\u20137.","journal-title":"J Infect Chemother"},{"key":"435_CR27","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/PL00002150","volume":"96","author":"C Niederau","year":"2001","unstructured":"Niederau C, Rolfs A, vom Dahl S, et al. [Diagnosis and therapy of Gaucher disease. Current recommendations of German therapy centers in the year 2000]. Med Klin (Munich). 2001;96:32\u20139.","journal-title":"Med Klin (Munich)"},{"key":"435_CR28","first-page":"851","volume":"186","author":"G Schaison","year":"2002","unstructured":"Schaison G, Caubel I, Belmatoug N, Billette de Villemeur T, Saudubray JM. [French results of enzyme replacement therapy in Gaucher\u2019s disease]. Bull Acad Natl Med. 2002;186:851\u201361.","journal-title":"Bull Acad Natl Med"},{"key":"435_CR29","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1556\/OH.2012.29281","volume":"153","author":"P Juh\u00e1sz","year":"2012","unstructured":"Juh\u00e1sz P, Toth B, Marodi L, Erdos M. [Enzyme replacement therapy for Gaucher disease introduced in late adulthood]. Orv Hetil. 2012;153:264\u201370.","journal-title":"Orv Hetil"},{"key":"435_CR30","unstructured":"Hansen GL, Lund AM, Borresen ML. [Splenomegaly and failure to thrive as a result of Gaucher disease]. Ugeskr Laeger. 2015;177."},{"key":"435_CR31","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/archneur.1989.00520460115022","volume":"46","author":"LB Krupp","year":"1989","unstructured":"Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46:1121\u20133.","journal-title":"Arch Neurol"},{"key":"435_CR32","doi-asserted-by":"crossref","first-page":"5106","DOI":"10.1200\/JCO.2007.12.2341","volume":"25","author":"SF Garcia","year":"2007","unstructured":"Garcia SF, Cella D, Clauser SB, et al. Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative. J Clin Oncol. 2007;25:5106\u201312.","journal-title":"J Clin Oncol"},{"key":"435_CR33","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jpsychores.2012.10.011","volume":"74","author":"Z Butt","year":"2013","unstructured":"Butt Z, Lai JS, Rao D, Heinemann AW, Bill A, Cella D. Measurement of fatigue in cancer, stroke, and HIV using the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) scale. J Psychosom Res. 2013;74:64\u20138.","journal-title":"J Psychosom Res"},{"key":"435_CR34","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/rheumatology\/keq454","volume":"50","author":"KB Norheim","year":"2011","unstructured":"Norheim KB, Jonsson G, Omdal R. Biological mechanisms of chronic fatigue. Rheumatology (Oxford). 2011;50:1009\u201318.","journal-title":"Rheumatology (Oxford)"},{"key":"435_CR35","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","volume":"324","author":"NW Barton","year":"1991","unstructured":"Barton NW, Brady RO, Dambrosia JM, et al. Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher\u2019s disease. N Engl J Med. 1991;324:1464\u201370.","journal-title":"N Engl J Med"},{"key":"435_CR36","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.clineuro.2010.12.005","volume":"113","author":"GK Papadimas","year":"2011","unstructured":"Papadimas GK, Spengos K, Konstantinopoulou A, et al. Adult Pompe disease: clinical manifestations and outcome of the first Greek patients receiving enzyme replacement therapy. Clin Neurol Neurosurg. 2011;113:303\u20137.","journal-title":"Clin Neurol Neurosurg"},{"key":"435_CR37","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ymgme.2013.03.016","volume":"109","author":"D Gungor","year":"2013","unstructured":"Gungor D, de Vries JM, Brusse E, et al. Enzyme replacement therapy and fatigue in adults with Pompe disease. Mol Genet Metab. 2013;109:174\u20138.","journal-title":"Mol Genet Metab"},{"key":"435_CR38","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1200\/JCO.2013.53.4495","volume":"32","author":"JE Bower","year":"2014","unstructured":"Bower JE, Bak K, Berger A, et al. Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical oncology clinical practice guideline adaptation. J Clin Oncol. 2014;32:1840\u201350.","journal-title":"J Clin Oncol"},{"key":"435_CR39","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2147\/TCRM.S56063","volume":"10","author":"HK Yuen","year":"2014","unstructured":"Yuen HK, Cunningham MA. Optimal management of fatigue in patients with systemic lupus erythematosus: a systematic review. Ther Clin Risk Manag. 2014;10:775\u201386.","journal-title":"Ther Clin Risk Manag"},{"key":"435_CR40","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fneur.2014.00177","volume":"5","author":"F Khan","year":"2014","unstructured":"Khan F, Amatya B, Galea M. Management of fatigue in persons with multiple sclerosis. Front Neurol. 2014;5:177.","journal-title":"Front Neurol"},{"key":"435_CR41","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s11136-011-0009-2","volume":"21","author":"RG Elbers","year":"2012","unstructured":"Elbers RG, Rietberg MB, van Wegen EE, et al. Self-report fatigue questionnaires in multiple sclerosis, Parkinson\u2019s disease and stroke: a systematic review of measurement properties. Qual Life Res. 2012;21:925\u201344.","journal-title":"Qual Life Res"},{"key":"435_CR42","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jpainsymman.2007.08.019","volume":"37","author":"L Whitehead","year":"2009","unstructured":"Whitehead L. The measurement of fatigue in chronic illness: a systematic review of unidimensional and multidimensional fatigue measures. J Pain Symptom Manage. 2009;37:107\u201328.","journal-title":"J Pain Symptom Manage"},{"key":"435_CR43","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1006\/bcmd.1997.0137","volume":"23","author":"CE Hollak","year":"1997","unstructured":"Hollak CE, Evers L, Aerts JM, van Oers MH. Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. Blood Cells Mol Dis. 1997;23:201\u201312.","journal-title":"Blood Cells Mol Dis"},{"key":"435_CR44","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s10545-007-0715-7","volume":"30","author":"M Langeveld","year":"2007","unstructured":"Langeveld M, Endert E, Wiersinga WM, Aerts JM, Hollak CE. Hypermetabolism in Gaucher disease type I is not associated with altered thyroid hormone levels. J Inherit Metab Dis. 2007;30:985.","journal-title":"J Inherit Metab Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-016-0435-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,19]],"date-time":"2022-06-19T03:31:59Z","timestamp":1655609519000},"score":1,"resource":{"primary":{"URL":"http:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-016-0435-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,29]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["435"],"URL":"https:\/\/doi.org\/10.1186\/s13023-016-0435-x","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,29]]},"article-number":"53"}}